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The model variables, i x , are defined in Table S1 and the kinetic expressions are given in Table   S2 , where i k 's represent model kinetic parameters, and i  's are constant factors that describe the inhibitory effect of palmitic acid and T2D. Symbols i x and i v are also represented in Figure S1 .
where j i K represent the equilibrium transcription factor-promoter dissociation constants, j i r the ratio of j i K 's when transcription factor j (either HNF1A or FOXA2) is bound to a promoter alone and in the presence of the other transcription factor, 01 i w  are modulation coefficients subject to the following relationship:
Modules I-V of the model were solved at steady-state with Mathematica (Wolfram Research Inc.), the analytical expressions for the state variables were then implemented in MATLAB (The MathWorks) and integrated with equations of Module VI. The complete MATLAB model is reported as Text S3.
Model Parameters. The human experimental data are summarized in Table S3 (2). As they are given by ratios between different component concentrations at steady-state, an absolute value for the model parameters could not be identified. Thus, the model was scaled, according to a dimensional analysis (3), with an arbitrary concentration of RNA, RNA x , and protein, pr x , and a time factor,  . The ratio pr RNA xx was also fitted to the experimental data. However, all the results presented are independent from this scaling. An analogous definition holds for transcription factors bound to GLUT-1 and GLUT-2 genes. Parameter estimation was performed by a two-step approach: first, a heuristic search method, the genetic algorithm, was used to span the parameter space randomly, avoiding local minima; then, a simplex search method, implemented by the fmincon function in MATLAB, was applied in order to minimize the cost function locally. The cost function was defined as the sum of leastsquare deviations of model outputs from experimental data, weighted by the experimental variability of each data. The outcome of the parameter estimation procedure included multiple sets of parameter values that were scored according to the value of the cost function. The parameter set having the lowest cost function value, reported in Table S4 , was used in all computations in the Main Text. The comparison of model output using this parameter set and the experimental data is shown in Figure S2 .
Sensitivity Analysis. The sensitivity analysis results, shown in Figure 5 in the Main Text, were investigated for robustness to uncertainty in parameter values ( Figure S3 ). A normally distributed noise, with standard deviation of 10% (according to the mean width of the confidence intervals of the parameters), was added to the parameter values to obtain 200 parameter sets, half perturbing a single parameter ( Figure S3 A) and half perturbing 10 random parameters at once (Figure S3 B) . The relative sensitivity coefficients were calculated with the different parameter sets to investigate the effect of a change in the RNA content of HNF1A, FOXA2, MGAT4A, GLUT1 and GLUT2 genes on the steady-state GK rate, at an extra-cellular glucose concentration of 16.8 mM. Figure S3 shows the results of the sensitivity analysis. The trend of Figure 5 is confirmed in both cases ( Figure S3 A and B), with a higher standard deviation in Figure S3 B respect to Figure S3 A. In each case the relative sensitivity coefficients were compared using one-way ANOVA with Tukey post-test, with p<0.05 indicating significance. Each pair comparison resulted significant, showing that the sensitivity analysis shown in Figure 5 is robust to both single and multiple parameter uncertainty. The sensitivity analysis above was performed using small changes in the parameters to calculate the sensitivity coefficients by numerically approximating the partial derivatives around the steady-state. Since pharmacological interventions would introduce much larger changes in the network, we also performed a sensitivity analysis for larger changes in parameter values, 25% of their nominal value, to capture the nonlinear behavior of the network. Figure S4 shows the results of this analysis and confirms the trend seen in Figure S3 B, indicating highest sensitivity to the perturbation of MGAT4A RNA. However, this analysis only partially supports the identification of the most promising pharmacological targets, because such large changes may induce secondary network responses not accounted for in the presented model structure. x GLUT-1 RNA 10,1
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Figure S2. Comparison of experimental data described in

